Log in or Sign up for Free to view tailored content for your specialty!
Steatohepatitis/Metabolic Liver Disease News
Lifestyle intervention leads to NAFLD remission regardless of obesity
Lifestyle intervention was effective in treating nonalcoholic fatty liver disease in both patients with and without obesity, with weight reduction predicting remission of NAFLD in patients without obesity, according to data published in Journal of Hepatology.
NASH Network launches real-world evidence pilot study
The NASH Network, in collaboration with the Kinetix Group and partnered with Echosens, launched a real-world evidence study to optimize care delivery for patients with nonalcoholic steatohepatitis, according to a press release.
Log in or Sign up for Free to view tailored content for your specialty!
Early warning score accurately predicts mortality risk in liver disease
The National Early Warning Score accurately identified patients with chronic liver diseases at risk for death, admission to the intensive care unit or cardiac arrest within a 24-hour period, according to a recently published study.
Simtuzumab ineffective in phase 2b trials for NASH-related fibrosis
Results of two phase 2b trials showed that simtuzumab was ineffective in reducing fibrosis or hepatic venous pressure gradient among patients with bridging fibrosis or cirrhosis associated with nonalcoholic steatohepatitis.
MELD-Na allocation improves liver transplant waitlist outcomes
Liver allocation based on MELD-Na score improved transplant waitlist outcomes and provided significant benefit to hyponatremic patients, according to recently published data.
Chronic liver disease hospitalizations outpace other chronic diseases
Patients with chronic liver disease had increasing rates of hospitalization, longer hospital stay, more readmissions and less access to post-acute care compared with patients with other chronic diseases, according to a recently published study.
Prometic fibrosis candidate reduces hepatic stellate cell activation
Prometic announced that results from recent studies of its lead candidate PBI-4050 showed that the therapy reduced activation of hepatic stellate cells and decreased liver fibrosis through modulation of the LKB1-AMPK-mTOR pathway, according to a press release.
8 recent reports on grants, approvals in clinical liver research
The FDA recently approved a thrombocytopenia therapy for adults with chronic liver disease and a combination therapy for advanced metastatic hepatocellular carcinoma. Along with these advancements, multiple societies have recently provided grants or investments into liver disease research.
Primary hypothyroidism associated with increased risk for NAFLD
The presence of primary hypothyroidism is associated with a 42% increased risk for image-defined or biopsy-proven nonalcoholic fatty liver disease, or NAFLD, with risk increasing across different definitions for diagnosing hypothyroidism, according to findings from a meta-analysis published in Thyroid.
Animal protein linked to NAFLD risk in older, overweight patients
Results of a large population-based study showed that high intake of animal-derived protein correlated with nonalcoholic fatty liver disease among older, overweight Caucasians, independent of well-known risk factors.